With reference to letter dated 27 October 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter and six months period ended 30 September 2026 and pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved Unaudited Standalone and Consolidated Financial Results for the quarter and six months period ended 30th September 2026, as recommended by Audit Committee; Unsecured loan of an aggregate amount of USD 1 million to Hester Biosciences Africa Limited (Hester Africa), foreign wholly-owned subsidiary in Tanzania, in one or more tranches. The loan is being extended for business and general corporate purposes, working capital requirement etc., subject to compliance with the applicable laws. They attached the approved unaudited standalone and consolidated financial results and limited review reports; and a Press Release issued in this regard. The details in this regard, pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, is enclosed as Annexure A. They will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 am (IST) and concluded at 11:05 am (IST).
The above information is a part of company’s filings submitted to BSE.